BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int. 2014;34 Suppl 1:146-153. [PMID: 24373092 DOI: 10.1111/liv.12398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Martín Mateos RM, Moreira Vicente VF, Tavío Hernández E, Cuño Roldán JL, Téllez Villajos L, Aicart Ramos M, Arribas Anta J, Zaera de la Fuente C, Albillos Martínez A. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations]. Gastroenterol Hepatol 2015;38:305-12. [PMID: 25636371 DOI: 10.1016/j.gastrohep.2014.12.001] [Reference Citation Analysis]
3 Gill US, Kennedy PT. Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Rev Anti Infect Ther 2014;12:1045-53. [PMID: 25052517 DOI: 10.1586/14787210.2014.940899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, Song Z, He W, Sun Y, Guo JT, Li W. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog 2016;12:e1005893. [PMID: 27783675 DOI: 10.1371/journal.ppat.1005893] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
5 Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 2015;116:79-91. [PMID: 26377741 DOI: 10.1093/bmb/ldv039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Zhang W, Xie Q, Ning Q, Dou X, Chen X, Jia J, Xie Y, Ren H. The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: A review of published literature. J Viral Hepat 2017;24:618-23. [DOI: 10.1111/jvh.12695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Clemente MG, Vajro P. An update on the strategies used for the treatment of chronic hepatitis B in children. Expert Rev Gastroenterol Hepatol 2016;10:649-58. [PMID: 26752166 DOI: 10.1586/17474124.2016.1139450] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Reference Citation Analysis]
9 Leng XJ, Yan XB. Status and development of anti-HBV drugs based on "HBF drug watch". Shijie Huaren Xiaohua Zazhi 2016; 24(15): 2336-2346 [DOI: 10.11569/wcjd.v24.i15.2336] [Reference Citation Analysis]
10 Madeddu G, Ortu S, Garrucciu G, Maida I, Melis M, Muredda AA, Mura MS, Babudieri S. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy. J Med Virol 2017;89:1208-14. [PMID: 27922198 DOI: 10.1002/jmv.24742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Lin S, Ye Q, Wang M, Wu Y, Weng Z, Zhu Y. Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation. Gastroenterology Res 2017;10:6-14. [PMID: 28270871 DOI: 10.14740/gr754w] [Reference Citation Analysis]
12 Yang HC, Kao JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect 2014;3:e64. [PMID: 26038757 DOI: 10.1038/emi.2014.64] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
13 Ozaras R, Khodor H, Yetim N, Unal UK, Demirhan YE, Gultekin G, Isal B. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015;13:1457-68. [PMID: 26414781 DOI: 10.1586/14787210.2015.1093934] [Reference Citation Analysis]
14 Orlando R, Foggia M, Maraolo AE, Mascolo S, Palmiero G, Tambaro O, Tosone G. Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis. 2015;34:1059-1070. [PMID: 25678010 DOI: 10.1007/s10096-015-2341-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
15 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kao JH, Asselah T, Dou XG, Hamed K. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol 2017;32:73-81. [PMID: 27515408 DOI: 10.1111/jgh.13512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016;43:43-8. [PMID: 26523639 DOI: 10.1016/j.ijid.2015.10.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]